Our team is happy and proud to have been voted as the winner for pitching our MTHFD1/2 inhibitor program.
https://www.linkedin.com/feed/update/urn:li:activity:6948268990171365376
One-carbon Therapeutics to Present Trial-in-Progress Poster on ODIN Phase 1/2 Study ofTH9619 at the 2026 ASCO Annual Meeting
Solna, Sweden, May 29th, 2026. One-carbon Therapeutics AB, a clinical-stage
